World Pharma News Digest - 30.11.2009

0 views
Skip to first unread message

Ruslan David

unread,
Nov 30, 2009, 4:46:23 AM11/30/09
to worldph...@googlegroups.com
Novartis gains rights to two oral targeted investigational therapies 
Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effective treatment options. 
Read more... 
http://www.worldpharmanews.com/content/view/1039/1/
 
Lundbeck initiates clinical phase II trials with Lu AE58054 
H. Lundbeck A/S announced the initiation of a multi-centre, placebo-controlled, fixed-dose study of Lu AE58054 as add-on to donepezil in patients with moderate Alzheimer's disease. The clinical phase II study is planned to enrol approximately 270 patients. 
Read more... 
http://www.worldpharmanews.com/content/view/1038/1/
 
Innovations in Oncology Drug Discovery, Development & Delivery 
Webinar: December 1 & December 10, 2009.
Every day academics, diagnostic developers, biotech and pharma companies get closer to scientific breakthroughs in technology and methods that are applicable to oncology treatments. Given the sheer volume of such discoveries, it is becoming increasingly difficult for potential stakeholders to become aware of these advances and remain updated. 
Read more... 
http://www.worldpharmanews.com/content/view/1037/1/
 
ExL Pharma's European Digital Marketing and Public Relations Conferences 
Bayer Schering Pharma and ExL Pharma announced that the 2nd Annual Digital Pharma Europe and 2nd Annual European Public Relations and Communications Summit will be hosted at the Bayer Schering Pharma World Headquarters in Berlin, Germany on March 29-30, 2010. 
Read more... 
http://www.worldpharmanews.com/content/view/1036/1/
 
EU-funded researchers use gene therapy to slow brain disease 
The brain disease X-linked adrenoleukodystrophy (ALD) can be treated with a combination of gene therapy and blood stem cell therapy, new EU-funded research shows. The research is part of the X-ALD (X-linked adrenoleukodystrophy: pathogenesis, animal models and therapy) project, which received EUR 1.8 million under the 'Life sciences, genomics and biotechnology for health' Thematic area of the EU's Sixth Framework Programme (FP6). 
Read more... 
http://www.worldpharmanews.com/content/view/1035/1/
 
FDA Grants IBsolvMIR Orphan Drug designation in the treatment of diabetes patients in the U.S. 
TikoMed AB, a biotechnology company focused on development and commercialization of innovative treatments for immune diseases and cell therapies, today announced that IBsolvMIR® has been granted orphan drug designation for the prevention of graft rejection of pancreatic islet transplantation by the U.S. Food and Drug Administration (FDA). 
Read more... 
http://www.worldpharmanews.com/content/view/1034/1/
 
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility 
Today, Novartis officially inaugurated the US's first ever large-scale flu cell culture vaccine and adjuvant manufacturing facility in Holly Springs, North Carolina. The facility is a result of a partnership between Novartis and the US Department of Health and Human Services (HHS). 
Read more... 
http://www.worldpharmanews.com/content/view/1033/1/
 
Merck KGaA to Expand Research and Development Presence in China 
Merck KGaA announced plans to strengthen its global research and development (R&D) capabilities of its Merck Serono division by establishing a global R&D center in Beijing, China. Merck is planning to invest more than € 150 million and create more than 200 new qualified jobs over the next four years to set up the China R&D center and conduct R&D activities in China. 
Read more... 
http://www.worldpharmanews.com/content/view/1032/1/
 
PharmaNews.eu / Latest News
 
 
 
 
 
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer
http://www.pharmanews.eu/roche/392-european-medical-advisory-committee-does-not-recommend-approval-of-avastin-for-deadly-form-of-brain-cancer
 
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa
http://www.pharmanews.eu/shire/391-shire-submits-european-marketing-authorization-application-maa-for-velaglucerase-alfa
 
 
EMEA makes recommendations to minimise risk of nephrogenic systemic fibrosis with gadolinium-containing contrast agents
http://www.pharmanews.eu/emea/389-emea-makes-recommendations-to-minimise-risk-of-nephrogenic-systemic-fibrosis-with-gadolinium-containing-contrast-agents
 
Boehringer Ingelheim and GlaxoSmithKline back EFA's call for urgent improvements in care for people with lung disease
http://www.pharmanews.eu/boehringer-ingelheim/388-boehringer-ingelheim-and-glaxosmithkline-back-efas-call-for-urgent-improvements-in-care-for-people-with-lung-disease
 
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
 
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages